Filing Flows › Autolus Therapeutics (AUTL) › Q1 2026 › vs Q4 2025
Autolus Therapeutics (AUTL) Q1 2026 vs Q4 2025 (quarter over quarter)
Autolus Therapeutics's revenue rose $1.9M (+8%) from $24.3M in Q4 2025 to $26.2M in Q1 2026.
Autolus Therapeutics, Q1 2026: revenue $26.2M (+192% year over year), operating margin -227.0%, net loss $71.6M, operating cash flow −$65.3M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $26.2M | $24.3M | $1.9M | +8% |
| Net loss | $71.6M | $90.3M | −$18.7M | -21% |
| Costs & expenses | $97.8M | $116M | −$18.0M | -16% |
| Operating costs | $85.7M | $96.8M | −$11.0M | -11% |
| Interest & other, net | $11.2M | $19.0M | −$7.8M | -41% |
| Income tax | $863K | −$1.2M | $2.0M | — |
| Cost of revenue | $24.6M | $25.3M | −$762K | -3% |
| Research & development | $21.2M | $35.6M | −$14.4M | -40% |
| SG&A | $40.0M | $35.8M | $4.2M | +12% |
| Operating cash sources | $71.6M | $90.3M | −$18.7M | -21% |
| Depreciation & amortization | $2.2M | $2.1M | $67K | +3% |
| Share-based compensation | $3.6M | $3.4M | $122K | +4% |
| Working capital & other | $507K | $17.4M | −$16.9M | -97% |
| Cash used in operations | $65.3M | $67.3M | −$2.0M | -3% |
| Net loss absorbed | $71.6M | $90.3M | −$18.7M | -21% |
Questions
How much did Autolus Therapeutics's revenue grow quarter over quarter in Q1 2026?
Autolus Therapeutics's revenue rose $1.9M (+8%) from $24.3M in Q4 2025 to $26.2M in Q1 2026.